Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 6/20 | 0.52 |
| ▸ | DUSP3 | P51452 | 6/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.40 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30841977 | 0.85 | KIF11 (0.49) | PTPN7DUSP3HTR2ASLC6A4KCNH2 | |
| SCHEMBL296018 | 0.85 | KIF11 (0.49) | PTPN7DUSP3HTR2ASLC6A4KCNH2 | |
| SCHEMBL18199695 | 0.85 | PTPN7 (0.46) | PTPN7DUSP3HTR2ASLC6A4KCNH2 | |
| SCHEMBL3276040 | 0.82 | TAAR1 (0.52) | PTPN7DUSP3ARNR3C2 | |
| SCHEMBL15432480 | 0.82 | PTPN7 (0.53) | PTPN7DUSP3ARP2RX7NR3C2 | |
| SCHEMBL27814588 | 0.82 | PTPN7 (0.50) | PTPN7DUSP3ARP2RX7NR3C2 | |
| SCHEMBL10662203 | 0.82 | PTPN7 (0.47) | PTPN7DUSP3SLC6A4ARP2RX7 | |
| SCHEMBL12871166 | 0.81 | PTPN7 (0.49) | PTPN7DUSP3KCNH2ARP2RX7 | |
| SCHEMBL15692018 | 0.80 | FFAR4 (0.46) | PTPN7DUSP3AR | |
| SCHEMBL296838 | 0.80 | IDO1 (0.56) | HTR2ASLC6A4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11304952-B2 | Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor | CHEMOCENTRYX, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11154556-B2 | Methods of treating solid tumors with CCR2 antagonists | CHEMOCENTRYX, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-110950812-B | Triazole compound and application thereof in agriculture | 东莞市东阳光农药研发有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| CN-110950812-A | Triazole compound and application thereof in agriculture | 东莞市东阳光农药研发有限公司 | 2020-04-03 | — | — | CN | disclosed |
| US-20190209573-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-11 | — | — | US | disclosed |
| WO-2019136368-A2 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20190134049-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20080312216-A1 | PIPERAZINE AND [1,4]DIAZEPAN DERIVATIVES AS NK ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-12-18 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| US-7351742-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
| CN-1062555-C | Substituted benzyloxy carbonyl guanidine, its prepn. method, and application of the same as medicament and medicament containing the same | HOECHST AG (DE) | 2001-02-28 | — | — | CN | disclosed |
| EP-0748795-B1 | Substituted benzyloxycarbonyl guanidines as Na+/H+ exchange inhibitors, process for their preparation, their use as medicinal or diagnostic agents as well as medicament containing them | HOECHST AG (DE) | 2000-08-23 | — | — | EP | disclosed |
| US-6022899-A | EFFECTIVE INHIBITORS OF THE CELLULAR SODIUM PROTON ANTIPORTER | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-02-08 | — | — | US | disclosed |
| US-5753710-A | INHIBITORS OF THE CELLULAR SODIUM PROTON ANTIPORTER | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-19 | — | — | US | disclosed |
| CN-1145360-A | Substituted benzyloxy carbonyl guanidine, its prepn. method, and application of the same as medicament and medicament containing the same | HOECHST AG (DE) | 1997-03-19 | — | — | CN | disclosed |
| EP-0748795-A2 | Substituted benzyloxycarbonyl guanidines as Na+/H+ exchange inhibitors, process for their preparation, their use as medicinal or diagnostic agents as well as medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209573-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | PTPN7 859/4885DUSP3 2236/4885HTR2A 917/4885 |
| US-20080312216-A1 | PIPERAZINE AND [1,4]DIAZEPAN DERIVATIVES AS NK ANTAGONISTS | DRD3, KCND3, GRIN3A | PTPN7 1263/4885DUSP3 1120/4885HTR2A 149/4885 |
| US-11154556-B2 | Methods of treating solid tumors with CCR2 antagonists | CCR2, CXCR2, CCRL2 | PTPN7 859/4885DUSP3 2236/4885HTR2A 917/4885 |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | PTPN7 777/4885DUSP3 2147/4885HTR2A 348/4885 |
| US-20190134049-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | PTPN7 767/4885DUSP3 1004/4885HTR2A 1028/4885 |
| US-11304952-B2 | Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor | CCR2, PDCD1LG2, CD274 | PTPN7 767/4885DUSP3 1004/4885HTR2A 1028/4885 |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | PTPN7 767/4885DUSP3 1004/4885HTR2A 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.